Cure8 regulatory brief
The study tests whether common environmental chemicals (PFAS) could alter protein glycosylation and raise the later risk of IBD, which could point to preventable risk factors and early biomarkers.
Researchers, clinicians interested in IBD etiology and prevention, and patients/advocates concerned about environmental exposures
The study will measure hundreds of PFAS chemicals and detailed serum N-glycosylation (total and IgG) using high-resolution mass spectrometry in samples collected 1–10 years before IBD diagnosis from an active-duty military cohort (PREDICTS2).
Researchers will test associations between PFAS mixtures, glycosylation changes, and subsequent IBD risk and complications at diagnosis. The project also includes laboratory work to examine PFAS effects on the intestinal glycocalyx and colitis in mouse models to strengthen causal inference.
This is a funded research project record describing planned epidemiologic analyses and animal-model experiments; it does not report results. Interpret any future findings only after peer review and publication.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: National Institute of Diabetes and Digestive and Kidney Diseases - R01DK145743 - $698,943
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This project could introduce a novel, microbiome-targeted oral therapy for Crohn’s disease if the Phase II trial confirms safety and clinical benefit; that matters because many patients need new options when current...
If you or a loved one follow emerging IBD treatments, this update signals a new PALI-2108 program moving into Phase 2 for ulcerative colitis and planned Phase 2 testing in Crohn’s disease, plus a company focus on...
Researchers report links between copper-driven cell death pathways and IBD biology; identifying cuproptosis-related biomarkers or drugs could open new diagnostic or therapeutic avenues for people with Crohn's disease or...
